Accordingly, pharmacological blockade of OPN proved to be an effective strategy to enhance the sensitivity of leukemic cells to Ara-C-based chemotherapy, as demonstrated in a B-ALL mouse model [135], suggesting a possible translation of this result to a clinical contest. The gene discussed is SPP1; the disease is precursor B-cell acute lymphoblastic leukemia.